<DOC>
	<DOC>NCT00129168</DOC>
	<brief_summary>Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.</brief_summary>
	<brief_title>Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description>Purpose: Phase I: To Evaluate the safety of different doses of zosuquidar. Phase II: This study is designed to study the safety and effectiveness of zosuquidar when given with daunorubicin and cytarabine in newly diagnosed AML patients.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Newly diagnosed acute myeloid leukemia Ages 5575 years Acute promyelocytic leukemia (FAB M3) Patients must not have received prior chemotherapy for AML. Prior exposure to anthracycline Use of any investigational agent within 4 weeks prior to enrollment into the study For Phase II: Patients must be Pglycoprotein positive</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Leukemia, Myeloid</keyword>
	<keyword>Relapse</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Zosuquidar</keyword>
	<keyword>Daunorubicin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Acute</keyword>
	<keyword>AML</keyword>
	<keyword>Adult AML</keyword>
</DOC>